If this message board is any indication, and I believe it is, there is very little retail interest in this stock. One reason is that the retail investor might be seeing the company as a one trick pony. On the other hand, as indicated by the institutional analyst questions today, Institutions are beginning to see this company in a very different light. Over and over today, in response to questions asked, the CEO indicated the inroads the company is making in expanding the types of operations where the use of its equipment is effective in reducing hosital costs through the reduction of post operative complications.
When you begin to aggregate the number of procedures in which the company's equipment can play a valuable role it is beginning to approach millions not thousands. And therein is why Andersongordon's statement about the stock still being a 10 bagger plus is not unreasonable. Two years from now it will be the razor blades driving profitabilty not new razors. Two years from now the use of this equipment as the standard of care in multiple procedures is very realistic. By the time the retail investor community realizes what is going on here, the pps is going to be out of their reach.
I too am impressed with all the potential new applications and areas not even yet pursued. Molecules that can be manufactured to identify cancer cells, efficatious transfer and application of blood, bile, lymph....not just transfer or lack there of can be measured, but the rates of flows into and out of body organs and tissues. As an engineer I know how important this fine grained, targeted information is in identifying the "root cause" of system failures and inefficiencies. The possibility of micro surgery and even molecular level analysis opens treatments not even thought of today. The possibilities for Novadaq are comperable to those of Intuitive Surgicals. They are opening a new field. This is a new paradigm, a seminal point in medicine.
Don't miss this opportunity. They ussually only come once in a persons lifetime.